A denosine is a purine nucleoside released from hypoxic and ischemic tissues, where it acts via 4 subtypes (A 1 , A 2A , A 2B , A 3 ) of G protein-coupled cell surface receptors to restore homeostasis by increasing blood supply and decreasing energy demand. Adenosine increases blood flow through vasodilation of preexisting vasculature and by stimulating angiogenesis. Adenosine-modulated angiogenesis, suggested by experiments on skeletal muscle in the early 1980's, 1 was first demonstrated in 1986, through application of adenosine to the chicken chorioallantoic membrane (CAM) using Elvax pellets. 2 Hypoxia-induced angiogenesis in the CAM was reduced 66% by methyl-isobutyl-xanthine, a cAMP phosphodiesterase inhibitor and nonselective competitive adenosine receptor (AR) antagonist. 3 In vitro studies have convincingly established direct proangiogenic mechanisms for A 2A and A 2B ARs, which promote endothelial cell (EC) proliferation and VEGF release, 4, 5 and indirect roles for A 2A, A 2B , and A 3 ARs which stimulate release of proangiogenic growth factors and cytokines from smooth muscle 6 and inflammatory cells. 7, 8 A 1 AR-mediated modulation of angiogenesis has not been well-characterized.
Effects of A 1 AR activation on ECs remain speculative. A 1 AR message can be detected in ECs 9 ; however, the functional response to A 1 AR activation in ECs is not mitogenic, but related to thrombosis 10 and inflammation. 11 Although one study has suggested that A 1 ARs may promote EC tube formation, 12 the bulk of in vitro experimental data does not support a proangiogenic mechanism of direct EC activation by the A 1 AR.
Activation of A 2A , A 2B , and A 3 ARs has been shown to cause release of proangiogenic growth factors and cytokines from mast cells and monocytes. 7, 8 To our knowledge, no studies on human and rodent mast cells have identified A 1 AR expression or function; however, monocytes possess A 1 ARs, activation of which stimulates multi-nucleated giant cell formation and phagocytosis. 13, 14 A 1 AR activation also promotes chemotaxis in a subset of proangiogenic monocytoid cells, plasmacytoid dendritic cells, that concentrate in some tumors. 15 I-ABA ϩ10 nmol/L I-ABA in HE buffer, containing 10 g/mL ADA and 4.9 mmol/L MgCl 2 , were incubated with 10 to 20 g membrane protein at 25°C for 2 to 3 hours. NECA (150 mol/L) was used to define nonspecific binding. Saturation isotherms on A 2B receptors were done similarly using serial dilutions from a maximum concentration of 1 
Isolation of Human Monocytes
Sixty ml of human blood was obtained from each consenting subject according to the guidelines of the University of Virginia Investigational Review Board and Human Investigational Committee. Human peripheral mononuclear cells were isolated according to the Histopaque 1077 protocol outlined by the manufacturer. Mononuclear cells were enriched for monocytes using the Dynal Biotech system according to the manufacturer's instructions. The enriched population was 65% monocytes as quantified by CD14 FITC labeling and fluorescence activated cell sorter (FACS) analysis, the other 35% being predominantly lymphocytes. These cells were further enriched for monocytes (Ͼ90%) by plating with subsequent removal of nonadherent cells.
Human Peripheral Monocyte Culture
Enriched monocytes were cultured at 0.5ϫ10 6 per mL in DMEM/ F12, 365 mg/L L-glutamine, and 100 U/mL Penicillin/Streptomycin with either DMSO vehicle (Ͻ0.05%), CPA 5 nmol/LϮantagonist ligand or CPA 50 nmol/LϮanti-VEGF antibody. Cells were cultured for 18 hours, the media removed, spun at 1000 RPM for 8 minutes, and the supernatant aliquoted and frozen at Ϫ80°C until analysis. Cell viability was Ͼ95% by trypan blue exclusion. VEGF, aFGF, and bFGF concentrations in supernatants were measured by ELISA.
Rat Thoracic Aortic Ring Angiogenesis Assay
All procedures are approved by the University of Virginia Animal Care and Use Committee. Rat thoracic aorta cultures were prepared as described by Nicosia 17 using rings embedded in collagen matrix prepared according to Elsdale and Bard. 23 
Statistical Analysis
Radioligand binding data were analyzed using GraphPad Prism 4.0. K i values were calculated as described by Linden. 22 Differences between 2 means were analyzed using Student t test; between multiple means using ANOVA with Bonferroni post-hoc analysis comparing each mean with control.
Results

Adenosine Stimulates Angiogenesis in the CAM
Dusseau et al reported previously that adenosine delivered to CAMs via Elvax pellets stimulated angiogenesis; however, Barnhill et al were unable to confirm this. 24 Using Elvax pellets impregnated with adenosine (3 mg) or vehicle we show that adenosine is proangiogenic in the CAM. Adenosine-containing pellets caused a 36% increase in the number of vessels intersecting the pellet margin compared with vehicle-impregnated control pellets ( Figure 1A ). Figure 1B ). The concentration was selected to be low enough to retain subtype selectivity, not necessarily to elicit a maximal response. Dose-dependent proangiogenic effects were observed in response to CPA with maximal effects seen at micromolar (mol/L) concentrations. Twenty nanomolar (nmol/L), 200 nmol/L, and 2 mol/L CPA (data not shown) were associated with 13%, 20%, and 31% increases in vessel number, respectively. By comparison, application of 0.5 g of VEGF, known to be a potent modulator of angiogenesis in the CAM, resulted in a 25% increase in vessel number ( Figure 2 ). The nonselective AR agonist NECA was used as a positive control, because a proangiogenic effect was expected based on prior in vivo and in vitro studies on A 2 ARs. There is no selective A 2B AR agonist; functional responses were attributed to this subtype if they were stimulated by NECA and blocked by the A 2B AR-selective antagonist, MRS-1754. Surprisingly, neither of the 25 (data not shown), elicited angiogenesis in the CAM, despite the fact that CGS21680 is a high affinity agonist for chicken A 2A ARs as demonstrated in studies showing it to be neuroprotective in chicken embryos. 26 The A 3 AR-selective ligand N 6 -(2-iodo)benzyl-5Ј-N-methylcarboxamidodoadenosine (IB-MECA) stimulated vessel growth in the CAM. The nonselective AR antagonist, xanthine amine congener (XAC), did not block baseline angiogenesis.
Control
Because there are significant species differences in pharmacology among A 1 , A 2B, and A 3 ARs, the subtypes that potentially mediate angiogenesis in the CAM, we cloned and pharmacologically characterized these chicken ARs to confirm that our ligand concentrations would differentiate among subtypes. Saturation equilibrium binding to recombinant receptors revealed adequate expression and high affinity binding for each (Table) . CPA was not selective for the chicken A 1 versus A 3 AR at 100 nmol/L, but was selective for the A 1 or A 3 AR compared with the A 2B receptor. Because A 2A AR agonists had no effect, CPA-stimulated angiogenesis in the CAM model was thought not to be A 2A AR-mediated and this receptor was not investigated further. Inhibition by WRC-0571, an A 1 AR antagonist with Ͼ700-fold selectivity for the chicken A 1 over the A 3 AR (Table) , was used to confirm that angiogenesis in the CAM in response to CPA was not A 3 AR-mediated. Figure 2 shows inhibition of the angiogenic response to 50 nmol/L CPA to below control levels by 1.0 mol/L WRC-0571, a concentration which would not be expected to completely antagonize effects of CPA on the chicken A 3 AR. Based on our radioligand binding data, 100 nmol/L CPA should not activate the A 2B AR (Ki Ͼ10 000). We believe that A 2B ARs in our system are well-coupled because our binding affinities for human A 2B ARs (data not shown) correlate well with published EC50s from functional assays using NECA and CPA, 27 and, compared with human, chicken A 2B ARs in our system have comparable or higher affinities for agonists tested. Our results suggest that the angiogenic response to 100 nmol/L CPA in the CAM is A 1 AR-mediated. A 3 AR-activation may also stimulate angiogenesis in the CAM, as suggested by the response to IB-MECA, which, at 100 nmol/L, should be selective for the chicken A 3 AR (see Table) .
CPA Does Not Promote Tube Formation in Ex Vivo Aortic Rings
We used the rat thoracic aortic ring model to test whether CPA would stimulate angiogenesis through direct effects on vascular cells. This ex vivo coculture model contains ECs, fibroblasts, and smooth muscle cells, but in the absence of injury is largely devoid of inflammatory cells. 17 Adenosine stimulates proliferation in ECs and fibroblasts, but inhibits proliferation from smooth muscle cells from most vascular beds, via interactions with A 2A or A 2B ARs. 5, 28, 29 In our hands, CPA failed to affect proliferation in human microvascular endothelial cells (HMECs) or in rat aortic vascular smooth muscle cells (data not shown). CPA (50 nmol/L) did not increase endothelial sprouting when applied directly to aortic rings ( Figure 3) . NECA, used as a positive control, increased tube formation 1.9-fold over vehicle (PϽ0.05), a response Ϸ60% of that observed to VEGF (10 ng/mL).
Conditioned Medium From CPA-Treated Monocytes Increases Endothelial Tube Formation in Aortic Rings
Given that CPA did not stimulate angiogenesis through direct interactions with vascular cells, we hypothesized that it may stimulate inflammatory cells to release proangiogenic factors. The 2 inflammatory cells most closely linked to angiogenesis, the mast cell and the monocyte, each possess multiple functional AR subtypes, but A 1 AR mRNA has not been identified in mast cells and has been in monocytes. 8, 30 In our hands, A 1 AR activation did not cause mast cell degranulation (data not shown).
We investigated the effects of A 1 AR stimulation on human monocytes isolated from peripheral blood. Our isolated monocytes express message for all 4 AR subtypes 30 (data not shown). By FACS, there was some lymphocytic contamination, but only a small fraction of lymphocytes, if any, possess A 1 ARs. 31 There was very little to no contamination with polymorphonuclear leukocytes, which express functional A 1 ARs.
Conditioned medium from CPA-stimulated (50 nmol/L) human monocytes increased the number of endothelial tube sprouts from aortic rings by 48% compared with control rings treated with medium from vehicle-exposed cells (135.4Ϯ12.4 tubes with CPA versus 91.0Ϯ9.2 with vehicle, PϽ0.05; Figure 4 ). Tube number was reduced to control levels in the presence of 50 nmol/L CPA ϩ1.5 mol/L WRC-0571 (98.0Ϯ10.4 vessels). The number of tubular sprouts in response to CPA-conditioned medium was similar to that of the VEGF (10 ng/mL) positive control (157.7Ϯ28.7 vessels) and was blocked by anti-VEGF antibody (10 g/mL; Figure 5 ).
VEGF Release From A 1 AR-Stimulated Human Monocytes
CPA (5 nmol/L) resulted in a 1.7-fold increase in VEGF release from human monocytes, from 581Ϯ277 to 802Ϯ355 pg/mL (PϽ0.05; Figure 6 ). This was blocked by the A 1 AR-selective antagonists WRC-0571 (200 nmol/L, PϾ0.05 versus control) and 1,3-dipropyl-8-cyclopentylxanthine (CPX, 300 nmol/L, PϾ0.05 versus control), but not by the A 2A AR-selective antagonist ZM241385 (50 nmol/L, PϽ0.05 versus control). These ligand concentrations were chosen to identify A 1 AR-mediated effects based on our previous pharmacologic characterization of human ARs. 32 Experiments were performed on unactivated monocytes. CPA did not cause aFGF or bFGF release from human monocytes (data not shown).
Discussion
Ours is the first study demonstrating A 1 AR-mediated angiogenesis in vivo and A 1 AR-mediated release of a proangiogenic factor (VEGF) from peripherally-derived monocytes. We screened subtype-selective AR ligands using the CAM model because it is a highly vascular surface in vivo that is well-characterized, inexpensive, convenient, and easy to image. Drawbacks are that the CAM is not mammalian, is not currently amenable to transgenic experimentation, and there is limited pharmacologic characterization of chicken receptors. Stimulation of angiogenesis by A 2 5,33,34 and A 3 ARs 8 was expected based on previous investigations, but discovering A 1 AR-modulated angiogenesis was surprising. We cloned and pharmacologically characterized the chicken A 1 , A 2B , and A 3 ARs to show that the ligand concentrations used in the CAM were selective for the chicken A 1 AR. We were not successful in cloning the chicken A 2A AR, but angiogenesis in the CAM was not stimulated by CSG21680, an agonist of known high affinity for the chicken A 2A AR, or to ATL-146e, another potent A 2A AR agonist. The CAM is a good in vivo screening model, but does not lend itself easily to mechanistic studies, so we used ex vivo and in vitro mammalian systems for these.
Whereas activation of A 2A and A 2B ARs 12,33,34 on ECs promotes angiogenesis, our evidence pointed against a direct angiogenic effect for the A 1 AR on ECs. A 1 AR activation stimulates blood vessel formation in the CAM model, which includes both vascular and inflammatory cells, but not in the aortic ring assay, a model largely devoid of inflammatory cells. A 1 AR expression in ECs has been reported, 35, 36 but the mitogenic properties of adenosine in ECs have been attributed to A 2 AR activation, 5, 33 with the role of the A 1 AR being 33 ; however, their data suggest that the A 1 AR may in some way modulate the angiogenic effects of adenosine on ECs because adenosinestimulated HREC proliferation is partly mediated through ERK activation, which is blocked by A 1 AR antagonists. Work by Lutty et al in canine retinal ECs suggests that A 1 AR activation may stimulate migration and tube formation, but not proliferation. 12 In our hands, CPA failed to stimulate proliferation of cultured HMECs. Further, our ex vivo results in the thoracic aortic ring suggest that activation of A 1 ARs in the rat aorta does not promote angiogenesis under the conditions we used. This having been said, expression and function of A 1 ARs in endothelium and smooth muscle may vary with the vascular bed studied, and with the physiologic milieu, including factors such as shear stress, hypoxia, reperfusion, and concentrations of glucose or lipid. In cultured cells, confluence may also influence A 1 AR expression and function. Finally, the role of A 1 AR in vascular cells may vary among species. We cannot exclude a role for the A 1 AR in modulating mitogenic effects on ECs from vascular beds other than the aorta, in species other than those we used, or in the presence of physiologic stressors not yet investigated.
Our observation that conditioned medium from CPAstimulated human monocytes promotes angiogenesis is consistent with the hypothesis that the A 1 AR can modulate angiogenesis through an indirect mechanism involving stimulation of inflammatory cells. Our data, in combination with other studies to date, are most consistent with the hypothesis that the A 1 AR-modulated response is monocyte-dependent. ARs are expressed on a variety of inflammatory cells, including neutrophils, 37 lymphocytes, 38 mast cells, 8 and monocytes/macrophages. 30 Of these, AR activation on mast cells 8 and monocytes/macrophages 7 has been most convincingly associated with angiogenesis. These effects have previously been attributable to A 2 7,8 or A 3 8 AR subtypes. We did 
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not observe mast cell degranulation in response to A 1 AR agonists. Although monocytes used for our studies are selected in a 2-step process using cell surface markers and substrate adherence, there are some residual contaminating lymphocytes. We do not observe significant contamination with neutrophils, making it unlikely that they are responsible for the angiogenic effects of CPA-conditioned medium. Conceivably A 1 AR-mediated angiogenic effects could involve contaminating lymphocytes, but others have shown that only a small fraction of circulating lymphocytes express the A 1 AR. 31 Functional A 1 ARs are present on monocyte/macrophages, modulating phagocytosis, chemotaxis, and multinucleate giant cell formation. [13] [14] [15] We show that one possible mechanism for A 1 AR-mediated angiogenesis in vivo is via effects on monocytes. The response may depend on interactions between more than one subpopulation of inflammatory cells, of which the monocyte is one. The A 1 AR may also have direct proangiogenic effects on vascular cells in vivo.
On the surface, our results might appear to contradict observations by Leibovich et al that murine peritoneal macrophages do not release VEGF in response to A 1 AR agonist. 7 Several explanations may reconcile the apparent discrepancy. First, as in mast cells, 39 there may be differences among species in the expression and function of AR subtypes in monocytes/macrophages. We used human monocytes derived from peripheral blood, whereas Leibovich et al used tissueresident intraperitoneal murine macrophages. Second, A 1 AR expression in monocytes and macrophages changes with culture conditions and cellular differentiation. 30, 40 The tissue resident macrophages studied by Leibovich et al would be expected to have significant phenotypic differences from our cultured peripheral blood monocytes. We confirmed the presence of message for the AR subtypes in our monocytes using RT-PCR and sequencing (data not shown), obtaining results similar to those previously reported by Theile et al. 30 Characterization of the role of the A 1 AR in subpopulations of monocytes and macrophages is not as well-developed as for the A 2A AR, but there is evidence that the A 1 AR is functionally significant in subsets of monocytic cells. Haskò et al have described differential chemokine release in response to activation of A 1 and A 2 AR subtypes in the RAW 264.7 macrophage cell line, suggesting that these receptors modulate distinct effects in these cells. 41 Further, adenosine stimulates chemotaxis of plasmacytoid dendritic cells isolated from peripheral blood via an A 1 AR-mediated mechanism. 15 This subpopulation of dendritic cells has been observed in high numbers in some forms of malignancy, where they induce angiogenesis. 42 Finally, it is possible that A 1 ARs in monocytes/macrophages are upregulated in response to specific physiologic stresses. Our studies were performed in systems unperturbed by hypoxic, oxidative, inflammatory, or glycemic stressors. There is evidence that alterations in expression of A 1 ARs on monocyte/macrophage cells are associated with some types of inflammatory diseases, including multiple sclerosis 43 and pulmonary damage associated with adenosine deaminase deficiency. 44 To our knowledge, this study is the first description of A 1 AR-mediated VEGF release, although A 2A , A 2B , and A 3 ARs have each been shown to regulate VEGF expression in a context-specific fashion. 4, 6, 45, 46 In previous studies the effects of adenosine on VEGF release have depended on the AR subtype activated, the species, the tissue, and the presence of specific physiologic stresses. In our cultured monocytes, the magnitude of VEGF release is modest, perhaps because our cultured cells were not exposed to another activating stimulus, which has been shown to be important for A 2 ARmodulated VEGF release in macrophages. A 2A AR activation synergistically increases VEGF release from LPS-treated, but not hypoxic, murine intraperitoneal macrophages 7 supporting the hypothesis that AR subtypes are differentially responsive to specific metabolic stresses, allowing specificity in response. Observations in other inflammatory cells support this hypothesis. Feoktistov et al 8 
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Monocyte/ Macrophage Figure 7 . Overview of proangiogenic effects of AR subtypes. On monocytes/ macrophages, adenosine (Ado) activation of A 1 (this report) and A 2A ARs 7 promotes VEGF release. LPS and the A 2A AR synergistically amplify VEGF release from macrophages. 7 On mast cells, A 2B AR activation causes release of VEGF and IL-8; and A 3 AR, angiopoietin 2 (Ang2). 8 A 2A ARs on smooth muscle cells (SMCs) 6 and some ECs 4 modulate VEGF release. A 2A ARs inhibit thrombospondin 1 (Tsp1) production by ECs. 47 A 2B ARs on ECs are upregulated by hypoxia and promote release of VEGF and IL-8. 5, 48, 49 taxis, whereas A 2A AR activation decreased phagocytosis and inhibited oxidative burst. 37 We have not yet explored stimuli potentially synergistic with A 1 AR agonists for VEGF release in the monocyte or the macrophage. It is also possible that A 1 AR activation on monocytes and macrophages promotes release of angiogenic factors other than VEGF, but we have not yet identified them. Figure 7 is an overview of proangiogenic effects associated with AR activation on vascular and inflammatory cells.
In conclusion, we have demonstrated that A 1 AR activation elicits an angiogenic response in vivo and promotes VEGFrelease from cultured monocytes.
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